Webinar for US Health Care Professionals

Early-Relapsed t(4;14) Myeloma

K36-MMSET-001 Clinical Trial Opportunity

About Webinar

As treatment options for relapsed multiple myeloma evolve, biomarker-driven clinical trials may offer new opportunities for patients with t(4;14) disease.

Watch this on-demand educational webinar to learn when to consider referring patients with early relapsed t(4;14) multiple myeloma and hear an overview of the K36-MMSET-001 clinical trial evaluating gintemetostat (KTX-1001), an investigational oral NSD2 inhibitor.

Topics include:

- The significance of t(4;14) in relapsed multiple myeloma
- Identifying patients who may be eligible for referral
- An overview of the K36-MMSET-001 clinical trial
- Participating study sites and referral pathways for your patients